Logo

Henlius Entered into a License Agreement with Eurofarma for Three Biosimilar Products in Latin America

Share this

Henlius Entered into a License Agreement with Eurofarma for Three Biosimilar Products in Latin America

Shots:

  • Henlius to receive a total value of ~$50.5M including a $4.5M up front. The companies collaborated to develop, manufacture, and commercialize Henlius' 3 products i.e., Hanlikang (rituximab, biosimilar), Hanquyou (trastuzumab, biosimilar) & Hanbeitai (bevacizumab biosimilar) in 16 Latin America countries
  • Eurofarma to acquire exclusive rights to Hanlikang in 12 countries, Hanquyou in 11 countries, and Hanbeitai in 15 countries including Mexico. Eurofarma will also obtain semi-exclusive rights in Brazil
  • This collaboration is a testament to Henlius' product quality, operational strength & continuance of Henlius’ goal of expanding its global footprint. Henlius & Farma de Colombia collaborated to promote Hanlikang's commercialization in Colombia, Peru, Ecuador & Venezuela

Ref: Henlius | Image: Henlius

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions